vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and ECARX Holdings Inc. (ECX). Click either name above to swap in a different company.
ECARX Holdings Inc. is the larger business by last-quarter revenue ($323.3M vs $205.4M, roughly 1.6× COLLEGIUM PHARMACEUTICAL, INC). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -21.4%, a 29.6% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 6.5%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $-86.5M).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
ECARX Holdings Inc. is a global mobility technology provider specializing in integrated smart vehicle solutions, including in-vehicle infotainment systems, advanced driver assistance technologies, and connected car cloud services. It primarily partners with automotive manufacturers across the world, with a strong operational presence in the Chinese and European markets.
COLL vs ECX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $323.3M |
| Net Profit | $17.0M | $-69.1M |
| Gross Margin | 62.5% | 15.5% |
| Operating Margin | 29.6% | -20.2% |
| Net Margin | 8.3% | -21.4% |
| Revenue YoY | 12.9% | 6.5% |
| Net Profit YoY | 35.3% | 12.8% |
| EPS (diluted) | $0.48 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | — | ||
| Q3 25 | $209.4M | — | ||
| Q2 25 | $188.0M | $323.3M | ||
| Q1 25 | $177.8M | — | ||
| Q4 24 | $181.9M | — | ||
| Q3 24 | $159.3M | — | ||
| Q2 24 | $145.3M | $303.5M | ||
| Q1 24 | $144.9M | — |
| Q4 25 | $17.0M | — | ||
| Q3 25 | $31.5M | — | ||
| Q2 25 | $12.0M | $-69.1M | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $9.3M | — | ||
| Q2 24 | $19.6M | $-79.2M | ||
| Q1 24 | $27.7M | — |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | 15.5% | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | 22.6% | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 18.7% | -20.2% | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 21.9% | — | ||
| Q2 24 | 32.7% | -22.2% | ||
| Q1 24 | 34.1% | — |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 6.4% | -21.4% | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 13.5% | -26.1% | ||
| Q1 24 | 19.1% | — |
| Q4 25 | $0.48 | — | ||
| Q3 25 | $0.84 | — | ||
| Q2 25 | $0.34 | $-0.20 | ||
| Q1 25 | $0.07 | — | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $0.52 | $-0.23 | ||
| Q1 24 | $0.71 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $86.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $-293.7M |
| Total Assets | $1.7B | $494.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | — | ||
| Q3 25 | $285.9M | — | ||
| Q2 25 | $222.2M | $86.2M | ||
| Q1 25 | $197.8M | — | ||
| Q4 24 | $162.8M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $271.6M | $108.4M | ||
| Q1 24 | $318.0M | — |
| Q4 25 | $301.7M | — | ||
| Q3 25 | $274.8M | — | ||
| Q2 25 | $232.2M | $-293.7M | ||
| Q1 25 | $234.4M | — | ||
| Q4 24 | $228.8M | — | ||
| Q3 24 | $234.3M | — | ||
| Q2 24 | $216.6M | $-198.5M | ||
| Q1 24 | $222.2M | — |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | $494.9M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.1B | $555.0M | ||
| Q1 24 | $1.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $-82.0M |
| Free Cash FlowOCF − Capex | $122.4M | $-86.5M |
| FCF MarginFCF / Revenue | 59.6% | -26.7% |
| Capex IntensityCapex / Revenue | 0.3% | 1.4% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | — | ||
| Q3 25 | $78.4M | — | ||
| Q2 25 | $72.4M | $-82.0M | ||
| Q1 25 | $55.4M | — | ||
| Q4 24 | $84.6M | — | ||
| Q3 24 | $-9.0M | — | ||
| Q2 24 | $67.4M | $-57.1M | ||
| Q1 24 | $61.9M | — |
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $72.4M | $-86.5M | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | — | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $67.1M | $-64.9M | ||
| Q1 24 | $61.4M | — |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 38.5% | -26.7% | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | -21.4% | ||
| Q1 24 | 42.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | 2.6% | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | — | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
